Welcome to our dedicated page for Abvc Biopharma SEC filings (Ticker: ABVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ABVC BioPharma, Inc. filings document the regulatory record of a Nevada clinical-stage biopharmaceutical company focused on ophthalmology, CNS, and oncology/hematology programs. The company’s disclosures include Form 8-K reports for financial results and material events, proxy materials for annual shareholder meetings, board elections, and shareholder voting results.
ABVC’s SEC filings also cover governance and capital-structure matters, including unregistered common stock sales under Regulation S, voting-rights proxy arrangements connected to those sales, director and officer compensation arrangements, changes in the company’s independent registered public accounting firm, and formal reporting around shareholder approvals and corporate controls.
ABVC BioPharma, Inc. reported no revenue for the three months ended March 31, 2026 and a net loss of $1.69 million, compared with a $0.94 million loss a year earlier. Higher operating expenses, especially $0.79 million of stock-based compensation, drove the wider loss.
Cash and cash equivalents fell to $140,324 as of March 31, 2026, from $1.33 million in cash and restricted cash at year-end 2025, with operating activities using $894,243 of cash in the quarter. The company reported a working capital deficit of $4.74 million and disclosed that these conditions raise substantial doubt about its ability to continue as a going concern.
Total assets were $19.73 million, including $12.82 million of property and equipment, against total liabilities of $6.90 million. Stockholders’ equity attributable to ABVC was $10.77 million, and noncontrolling interests added $2.06 million. The company modestly strengthened equity through warrant exercises and private placements, increasing common shares outstanding to 25,767,664 at March 31, 2026 and 26,000,442 as of May 14, 2026.
ABVC BioPharma, Inc. notified the SEC it could not timely file its Form 10-Q for the period ended March 31, 2026 and submitted a Form 12b-25 explaining the delay. Management states it cannot finalize the XBRL exhibit without "unreasonable effort or expense" and expects to file within the prescribed extension period.
The notification, signed by Principal Executive Officer Uttam Patil on May 15, 2026, indicates routine contact information and confirms prior periodic reports have been filed. The filing does not disclose changes to results of operations.
ABVC BioPharma, Inc. reported results from its 2026 annual shareholder meeting held on March 26, 2026. A quorum was present, with 10,612,493 common shares representing 41.74% of the voting power entitled to vote.
Shareholders re-elected all director nominees, each receiving over ten million votes in favor. They also approved the reappointment of Simon & Edward, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 10,597,352 votes for, 12,291 against, and 2,850 abstentions.
In addition, shareholders approved the Plan Proposal, with 9,964,400 votes for, 643,419 against, and 4,674 abstentions, indicating broad support among those present for the company’s equity or incentive plan changes.
ABVC BioPharma, Inc. is asking shareholders to vote at its 2026 annual meeting, which will be held virtually via Zoom on March 26, 2026 at 10:00 a.m. EST. Shareholders of record as of January 26, 2026, when 25,423,654 common shares were outstanding, are entitled to one vote per share.
Key items include re‑electing 11 directors, ratifying Simon & Edward, LLP as independent auditor for 2026, and approving an amendment to the 2016 Equity Incentive Plan. The plan amendment would reset the share reserve so that, immediately after the change, it equals 15% of issued and outstanding common stock as of the meeting date, with a continuing 5% annual “evergreen” increase starting in 2027.
Shareholders must vote by proxy in advance; there will be no live voting during the virtual meeting, and signed proxies without specific instructions will be voted “FOR” all nominees and proposals, as recommended unanimously by the Board.
ABVC BioPharma files its annual report describing an early-stage biotech business focused on botanical drugs for CNS and oncology/hematology, plus one ophthalmic medical device. Revenue currently comes mainly from out-licensing intellectual property and CDMO manufacturing services.
The company reports seven drug candidates and one device in various Phase I/II programs for major depressive disorder, ADHD, cancer-related depression, myelodysplastic syndromes, pancreatic cancer and retinal detachment. It holds a broad patent estate across the U.S., Europe and Asia and operates a GMP facility through subsidiary BioKey.
ABVC highlights prior Nasdaq notifications for minimum bid price and stockholders’ equity deficiencies and notes that it subsequently regained compliance with Listing Rule 5550, avoiding a reverse split. The report cites an aggregate market value of non-affiliate common stock of $37 million as of June 30, 2025 and 25,440,407 common shares outstanding as of March 3, 2026. Extensive risk factors emphasize funding needs, lack of approved products, clinical and regulatory uncertainty, concentration of licensing relationships, and potential volatility of the stock.
ABVC BioPharma, Inc. is restating its unaudited quarterly results for the period ended September 30, 2025 after management concluded prior statements should no longer be relied upon. The company reversed $795,950 of previously recognized licensing revenue tied to payments from OncoX and ForSeeCon that were determined to be effectively funded by related party BioFirst or did not meet contractual funding conditions.
ABVC also changed how it valued land acquired from a director in Taiwan, increasing the recorded cost of the property by $798,486 to $4,656,461 based on the fair value of equity and warrants issued. For the nine months ended September 30, 2025, restated results show no revenue, a net loss of $5,360,496, and net cash used in operating activities of $2,398,717. The company reports a working capital deficit of $3,230,901 and states that these conditions raise substantial doubt about its ability to continue as a going concern, noting it will need improved operations, additional capital, or related-party support.
ABVC BioPharma, Inc. reported that its previously issued financial statements for the quarter ended September 30, 2025 should no longer be relied upon because of errors in revenue recognition and fair value measurement. The company reversed an aggregate $795,950 of licensing revenue from OncoX and ForSeeCon after determining much of the cash effectively came from related party BioFirst or did not meet contractual payment conditions, and reclassified those amounts to balances with BioFirst and OncoX.
ABVC also remeasured land acquired from director Shuling Jiang, concluding that the fair value of the equity and warrants issued provides a clearer measure than the prior appraisal-based value. This increased the recorded land cost by $798,486 to $4,656,461. The company identified a material weakness in internal control over financial reporting and plans to amend the affected Form 10-Q. Separately, ABVC’s 2025 Form 10-K shows total assets rising 179% to $21.06 million, driven mainly by strategic land and development-oriented assets in Asia.
ABVC BioPharma, Inc. is asking shareholders to approve three items at its 2026 virtual annual meeting on March 9, 2026. Shareholders will vote on re-electing 11 directors, ratifying Simon & Edward, LLP as auditor for 2026, and increasing shares under the 2016 Equity Incentive Plan.
The equity plan amendment would raise the plan reserve to an amount equal to 15% of the company’s 25,423,654 shares of common stock outstanding as of January 26, 2026, which is estimated at 3,813,548 shares, with a continuing 5% annual “evergreen” increase beginning in 2027.
ABVC BioPharma reports additional unregistered equity sales following a prior offshore offering. Between April 11 and May 27, 2025, the company sold 1,987,557 common shares to 43 Non-U.S. Persons under Regulation S, raising aggregate gross proceeds of about $1,289,750.
Between May 26, 2025, and January 6, 2026, ABVC accepted further subscriptions totaling $2,275,468 on the same terms, issuing 1,500,250 additional common shares at prices between $1.00 and $1.95 per share. These new shares equal about 5.92% of the company’s outstanding common stock as of this filing. Investors entered stock purchase agreements and Voting Rights Proxy Agreements transferring their voting rights to chairman Eugene Jiang. The securities were sold privately to accredited, Non-U.S. investors, are unregistered, and are subject to resale restrictions under U.S. securities laws.
ABVC BioPharma filed Prospectus Supplement No. 4 to its July 12, 2024 prospectus, registering 1,000,000 shares of common stock underlying a common stock purchase warrant. The supplement also attaches the company’s Q3 2025 Form 10‑Q. Shares outstanding were 24,301,089 as of October 30, 2025; this is a baseline figure, not the amount being offered.
For the nine months ended September 30, 2025, ABVC reported revenue of $795,950 and a net loss of $4,564,546. The company disclosed a working capital deficit of $2,434,951 and noted substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $192,068 with restricted cash of $661,843. Total assets rose to $21.18 million, reflecting land acquisitions and other noncurrent items.